← Back to Search

Nutrient Supplement

Ad-Chol-Pre for High Cholesterol (AdBiotech Trial)

N/A
Waitlist Available
Led By Gilbert R Kaats, PhD FACN
Research Sponsored by Integrative Health Technologies, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30 and 60 days
Awards & highlights

AdBiotech Trial Summary

The purpose of this study is to evaluate the effectiveness of a food-source nutrient containing bitter orange by comparing changes 45 blood chemistries and self-reported quality of life.

Eligible Conditions
  • High Cholesterol

AdBiotech Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30 and 60 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 30 and 60 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change from baseline in Total Cholesterol and LDL levels at 30 days
Change from baseline in Total Cholesterol and LDL levels at 60 days
Change from mid-point in Total Cholesterol and LDL levels at 60 days
Secondary outcome measures
Blood Chemistry Measurements
Number of participants with adverse effects
Self-reported Quality of Life

AdBiotech Trial Design

3Treatment groups
Active Control
Placebo Group
Group I: Ad-Chol-PreActive Control1 Intervention
A functional food ingredient designed to inhibit cholesterol absorption. ACP is a freeze dried defatted egg powder containing specific Anti-NPCIL1 (Niemann-Pick C1-like 1) IgY. NPC1L1 is known as a biological target of the cholesterol-uptake inhibitor, Ezetimibe.
Group II: Half-dose Ad-Chol-PreActive Control1 Intervention
A half-dose of the active comparator in arm one is administered. A functional food ingredient designed to inhibit cholesterol absorption. ACP is a freeze dried defatted egg powder containing specific Anti-NPCIL1 (Niemann-Pick C1-like 1) IgY. NPC1L1 is known as a biological target of the cholesterol-uptake inhibitor, Ezetimibe.
Group III: Capsule containing inactive component of defatted egg yolkPlacebo Group1 Intervention
Placebo capsule is filled with defat egg yolk only without specific IgY which is anti-NPC1L1 IgY, designed to look and taste the same as the active product capsule, but does not contain the active component.

Find a Location

Who is running the clinical trial?

Integrative Health Technologies, Inc.Lead Sponsor
5 Previous Clinical Trials
859 Total Patients Enrolled
Gilbert R Kaats, PhD FACNPrincipal InvestigatorIntegrative Health Technologies, Inc.
3 Previous Clinical Trials
435 Total Patients Enrolled
Harry G Preuss, MD MACNStudy ChairGeorgetown University Medical Center, Dept of Biochemistry, Medicine and Pathology
3 Previous Clinical Trials
435 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Study of Changes in Total Cholesterol Levels as a Function of Consuming a Supplement Designed to Improve Cardiovascular Health
Gilbert R Kaats 2013. "Study of Changes in Total Cholesterol Levels as a Function of Consuming a Supplement Designed to Improve Cardiovascular Health". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01890889.
All > Health > Cholesterol
~13 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top